Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage beneficial ownership in Row 11 above is based on a total of 220,528,649 shares of Class A Common Stock (as defined below) outstanding as of December 1, 2025, as reported on the Issuer's (as defined below) Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on December 4, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage beneficial ownership in Row 11 above is based on a total of 220,528,649 shares of Class A Common Stock outstanding as of December 1, 2025, as reported on the Issuer's Quarterly Report on Form 10-Q filed with the Commission on December 4, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage beneficial ownership in Row 11 above is based on a total of 220,528,649 shares of Class A Common Stock outstanding as of December 1, 2025, as reported on the Issuer's Quarterly Report on Form 10-Q filed with the Commission on December 4, 2025.


SCHEDULE 13G



 
TPG GP A, LLC
 
Signature:/s/ Martin Davidson
Name/Title:Martin Davidson / Chief Accounting Officer
Date:02/13/2026
 
COULTER, JAMES G
 
Signature:/s/ Gerald Neugebauer
Name/Title:Gerald Neugebauer, on behalf of James G. Coulter (1)
Date:02/13/2026
 
WINKELRIED JON
 
Signature:/s/ Gerald Neugebauer
Name/Title:Gerald Neugebauer, on behalf of Jon Winkelried (2)
Date:02/13/2026

Comments accompanying signature:  (1) Gerald Neugebauer is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Coulter on February 7, 2024 (SEC File No. 001-41617). (2) Gerald Neugebauer is signing on behalf of Mr. Winkelried pursuant to an authorization and designation letter dated January 10, 2024, which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Winkelried on February 7, 2024 (SEC File No. 001-41617).
Exhibit Information

Exhibit 1 - Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.* _______________ * Incorporated herein by reference to the Agreement of Joint Filing by TPG Group Holdings (SBS) Advisors, Inc., TPG GP A, LLC, TPG Advisors VII, Inc., TPG Advisors VI, Inc., TPG Advisors VI-AIV, Inc., TPG Asia Advisors VI, Inc., David Bonderman, James G. Coulter, Jon Winkelried and Karl Peterson dated as of January 18, 2022, which was previously filed with the Commission as Exhibit 1 to Amendment No. 4 to Schedule 13D filed by TPG GP A, LLC, David Bonderman, James G. Coulter and Jon Winkelried on January 18, 2022 with respect to the shares of common stock of Allogene Therapeutics, Inc.